Evidence map›Paper›PMID 35879048›Full record

ArticleGut2022

Microbial determinants of effective donors in faecal microbiota transplantation for UC.

Craig Haifer, Laurence Don Wai Luu, Sudarshan Paramsothy, Thomas J Borody, Rupert W Leong, Nadeem O Kaakoush

Abstract read
PubMed Publisher
In one paragraph

Article in Gut, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Application and prospects of fecal microbiota transplantation in cancer therapy.Frontiers in cellular and infection microbiology · 2026
    Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Craig Haifer *Concord Clinical School, University of Sydney, Sydney, NSW, Australia.
Laurence Don Wai Luu *School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0003-2516-2121
Sudarshan ParamsothyConcord Clinical School, University of Sydney, Sydney, NSW, Australia.
Thomas J BorodyCentre for Digestive Diseases, Sydney, NSW, Australia.
Rupert W LeongConcord Clinical School, University of Sydney, Sydney, NSW, Australia.
Nadeem O KaakoushSchool of Medical Sciences, University of New South Wales, Sydney, NSW, Australia n.kaakoush@unsw.edu.au.ORCID http://orcid.org/0000-0003-4017-1077
The University of Sydney · AUUNSW Sydney · AUCentre For Digestive Diseases · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveFaecal microbiota transplantation (FMT) has variable efficacy in treating UC. Recently, oral lyophilised FMT was found to induce remission in patients with UC, with one donor having 100% efficacy compared with a second donor (36% efficacy). We characterised differences in the gut microbiota of these two donors with the aim of improving FMT donor selection.

designFaecal samples from the two donors were collected over a period of 44 (donor 1) or 70 (donor 2) weeks. The microbiome and metabolome were profiled using shotgun metagenomics and untargeted metabolomics

resultsGut microbiome long-term stability was highly evident in the effective donor. Donor microbiota species evenness was a robust feature associated with clinical efficacy across two clinical trials of FMT in UC, leading to increased donor species engraftment in patients. Alpha diversity and beta diversity of donor gut microbiotas significantly differed. 90 bacterial species and one archaeon were differentially abundant between donors, 44 of which were >0.1% in relative abundance. 17/44 species were enriched in the effective donor, 11 of which (64.7%) were assembled into high-quality genomes that were prevalent (≥75% samples) in that donor, and six showed evidence of engraftment in patients. Taxonomic differences between donors translated to substantial microbial functional differences that were validated using metabolomics.

conclusionDonor microbiota stability and species evenness were identified as novel metrics that were associated with therapeutic efficacy in UC, beyond individual microbial species or metabolites. These metrics may represent community resilience that translates to better engraftment in the host. TRIAL REGISTRATION NUMBER: ACTRN12619000611123.

Indexed as

COLONIC MICROFLORAIBDULCERATIVE COLITIS

Identifiers

PMID35879048
OpenAlexW4287509812

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.